Log in to search using one of your social media accounts:

 

Novartis and The Max Foundation to provide cancer access programme in lower-income countries
Novartis has entered a new collaboration with The Max Foundation to support continued access to treatment free of charge for almost 34,000 patients suffering from chronic myeloid leukaemia (CML), gastrointestinal tumours (GIST) and other rare cancers … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 25, 2017 Category: Pharmaceuticals Source Type: news

Prostaglandin EI inhibits leukemia stem cells
(University of Iowa Health Care) Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 25, 2017 Category: Cancer & Oncology Source Type: news

Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers. The two organizations have been long-time collaborators in providing access to care for patients in lower-income countries through the Glivec International Patient Assistance Program (GIPAP), (Source: World Pharma News)
Source: World Pharma News - September 22, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Nigeria: Leukemia Patients Celebrate 10th World CML Day
[This Day] As patients of Chronic Myeloid Leukemia (CML) worldwide celebrate the 10th World CML Day today to raise awareness on a rare haematological disease that represents 15 to 20 per cent of all leukemia in adults and the needs of patients, a non-governmental organisation, Together Maxcare Foundation Nigeria, is pushing for more sensitivity to the plight of patients who have this rare type of leukemia. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 22, 2017 Category: African Health Source Type: news

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Media News)
Source: Roche Media News - September 18, 2017 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Investor Update)
Source: Roche Investor Update - September 18, 2017 Category: Pharmaceuticals Source Type: news

Verastem improves progression-free survival in Phase III trial for CLL and SLL
US-based biopharmaceutical firm Verastem has reported positive top-line results from the Phase III DUO clinical trial of duvelisib to treat relapsed or refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

Leukemia Drug Bosutinib Shows Promise for Inherited Kidney Disease Leukemia Drug Bosutinib Shows Promise for Inherited Kidney Disease
The tyrosine kinase inhibitor bosutinib, approved for chronic myeloid leukemia, reduced kidney growth rate in patients with autosomal dominant polycystic kidney disease (ADPKD) in a phase 2 study.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 31, 2017 Category: Intensive Care Tags: Nephrology News Source Type: news

EMA accepts Pfizer ’s bosulif Type II Variation application for Ph+ CML
The European Medicines Agency (EMA) has approved for review a Type II Variation application for the use of Pfizer ’s bosulif (bosutinib) to treat patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news

CML Blast Phase Outcomes Remain Poor in TKI Era, Prognostic Factors Identified
Patients with chronic myeloid leukemia in the blast phase pose a significant therapeutic challenge and have poor survival, even in the tyrosine kinase inhibitor era, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - August 9, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Optimizing Nilotinib Dose in CML Could Yield Higher Response Rates
Dose optimization of nilotinib is feasible and may help patients with chronic-phase chronic myeloid leukemia achieve molecular responses, according to results of a new study. (Source: CancerNetwork)
Source: CancerNetwork - July 31, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Cancer cells put the brakes on immune system
(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) In order for cancer cells to successfully spread and multiply, they must find a way to avoid the body's own immune system. Scientists at the German Cancer Research Center have published an explanation for how this occurs with chronic lymphatic leukemia (CLL). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 28, 2017 Category: Cancer & Oncology Source Type: news

CML Patients Approach Normal Life Expectancy With Imatinib Treatment
Treatment with imatinib results in good overall survival in patients with chronic myeloid leukemia, approaching a normal life expectancy, according to the CML-IV study. (Source: CancerNetwork)
Source: CancerNetwork - July 21, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

FDA Grants Priority Review for New Leukemia Option
The FDA has granted priority review status for two new indications of dasatinib (Sprycel), according to the drug ’s developer. (Source: CancerNetwork)
Source: CancerNetwork - July 20, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Pediatric Cancers Source Type: news

Sunesis starts dosing in Phase Ib/II trial of SNS-062 for B-cell malignancies
Sunesis Pharmaceuticals has started dosing patients in a Phase Ib/II clinical trial of SNS-062 to treat patients with B-cell malignancies such as chronic lymphocytic leukaemia (CLL), small lymphocytic leukaemia, Waldenstrom ’s macroglobulinemia and ma… (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2017 Category: Pharmaceuticals Source Type: news

New approach to leukaemia can help improve successful treatment
(University of Liverpool) New University of Liverpool research, presented at an international conference, confirms that a novel approach to the treatment of chronic myeloid leukaemia (CML) can safely increase treatment success and reduce negative side effects. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 12, 2017 Category: Biology Source Type: news

New approach to leukemia can help improve successful treatment
(University of Liverpool) New University of Liverpool research, presented at an international conference, confirms that a novel approach to the treatment of chronic myeloid leukemia (CML) can safely increase treatment success and reduce negative side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2017 Category: Cancer & Oncology Source Type: news

Treatment-Free Remission in CML Sustainable After Nilotinib
Approximately half of patients with chronic-phase CML who achieved a sustained deep molecular response with nilotinib were able to discontinue therapy and remain in treatment-free remission through 96 weeks. (Source: CancerNetwork)
Source: CancerNetwork - July 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia & Lymphoma News Source Type: news

FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 29, 2017 Category: American Health Source Type: news

Dasatinib in Children: An Effective Alternative to Imatinib Dasatinib in Children: An Effective Alternative to Imatinib
In children and adolescents with chronic-phase chronic myeloid leukemia, dasatinib shows response rates and safety similar to those seen in adults.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Adding Ublituximab to Ibrutinib Improves Relapsed CLL Response Rates
Adding the novel CD20 inhibitor ublituximab to ibrutinib offered improved response rates and greater depth of response over ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 23, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: World Pharma News)
Source: World Pharma News - June 23, 2017 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
Roche today announced new data from multiple studies of Venclexta ®/Venclyxto® (venetoclax), presented at the 22nd European Hematology Association (EHA) Annual Congress, 22-25 June, in Madrid. (Source: Roche Media News)
Source: Roche Media News - June 23, 2017 Category: Pharmaceuticals Source Type: news

Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
Roche today announced new data from multiple studies of Venclexta ®/Venclyxto® (venetoclax), presented at the 22nd European Hematology Association (EHA) Annual Congress, 22-25 June, in Madrid. (Source: Roche Investor Update)
Source: Roche Investor Update - June 23, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela ™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: Roche Media News)
Source: Roche Media News - June 23, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela ™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: Roche Investor Update)
Source: Roche Investor Update - June 23, 2017 Category: Pharmaceuticals Source Type: news

Immune Pharma starts enrolment in Phase I/II trial of Ceplene for CMML
Immune Pharmaceuticals has started patient recruitment for Phase I/II clinical trial of Ceplene (histamine dihydrochloride) to treat chronic myelomonocytic leukaemia (CMML) patients.   (Source: Drug Development Technology)
Source: Drug Development Technology - June 21, 2017 Category: Pharmaceuticals Source Type: news

Real Stories Of Americans Who Will Be Affected By The Proposed Changes To The ACA — And What YOU Can Do To Fight
With the proposed changes to the Affordable Care Act (ACA), 20 million Americans are at risk of losing their health care coverage. A survey, conducted by Brunswick Partners, found that “75 percent of Americans agree that the proposed changes to Medicaid in the AHCA are a bad idea. And that we should not allow 14 million Americans to become uninsured even if there is a potential to reduce Medicaid spending. These results are significant because they find majorities of Americans identifying as conservatives (55 percent), moderates (82 percent) and liberals (90 percent) are opposed to the AHCA’s Medicaid pro...
Source: Healthy Living - The Huffington Post - June 21, 2017 Category: Consumer Health News Source Type: news

TKI De-escalation Safe in Most CML Patients With Major Molecular Response
A de-escalation of tyrosine-kinase inhibitor dose was safe in the majority of patients with chronic myeloid leukemia with stable major molecular response. (Source: CancerNetwork)
Source: CancerNetwork - June 17, 2017 Category: Cancer & Oncology Tags: Chronic Myeloid Leukemia News Source Type: news

Dasatinib Is Safe, Effective in Pediatric Chronic Myeloid Leukemia
Dasatinib was safe and effective in pediatric patients with chronic myeloid leukemia, according to a new study, establishing the agent as a new standard of care for this population. (Source: CancerNetwork)
Source: CancerNetwork - June 13, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia News Pediatric Cancers Source Type: news

CAR T Cell/Ibrutinib Combination May Improve CLL Response Rates
Despite immune-related adverse events, concurrent ibrutinib and anti-CD19 CAR T-cell therapy may improve response rates in patients with chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Hematology Leukemia & Lymphoma News Source Type: news

Truxima (rituximab) for the Treatment of Cancer
ruxima ™ (rituximab) is the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, as well… (Source: Drug Development Technology)
Source: Drug Development Technology - June 8, 2017 Category: Pharmaceuticals Source Type: news

Janssen reports positive follow-up data from Phase III trial of Imbruvica for CLL
Janssen-Cilag International (Janssen) has reported positive data from a four-year follow-up period of its Phase III RESONATE trial of Imbruvica (ibrutinib) to treat relapsed / refractory (R/R) chronic lymphocytic leukaemia (CLL) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - June 6, 2017 Category: Pharmaceuticals Source Type: news

Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia
This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Jorge E. Cortes, MD Tags: Conferences/ASCO Hematology Chronic Myeloid Leukemia News Videos Hematologic Malignancies Source Type: news

Drug Helps Some Kids With Rare Type of Leukemia
Dasatinib prolonged survival in chronic myeloid leukemia patients, study says (Source: WebMD Health)
Source: WebMD Health - June 5, 2017 Category: Consumer Health News Source Type: news

Data at ASCO Show Consistent Progression-Free Survival Benefit in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated with Ibrutinib, Including Those with High-Risk Disease, with Up to Four Years of Follow-Up
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 5, 2017 Category: Pharmaceuticals Source Type: news

Cancer Drug Helps Some Kids With Rare Type of Leukemia
Dasatinib prolonged survival in chronic myeloid leukemia patients, study says (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 5, 2017 Category: Cancer & Oncology Tags: Oncology, Pediatrics, Pharmacy, News, Source Type: news

New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
IMBRUVICA effectively impacted cancerous cells while sparing non-cancerous white blood cells through one year of treatment This release corresponds to abstract #7524 NORTH CHICAGO, Ill., June 5, 2017 -- (Healthcare Sales & Marketing Network) -- IMBR... Biopharmaceuticals, Oncology AbbVie, IMBRUVICA, ibrutinib, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 5, 2017 Category: Pharmaceuticals Source Type: news

Cancer Drug, Dasatinib, Helps Some Kids With Rare Type of Leukemia
MONDAY, June 5, 2017 -- The cancer drug dasatinib shows promise in treating children with chronic myeloid leukemia (CML) caused by the gene BCR-ABL, also known as the Philadelphia chromosome, researchers report. " Despite the fact that there is a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 5, 2017 Category: General Medicine Source Type: news

Cancer Drug Helps Some Kids With Rare Type of Leukemia
Dasatinib prolonged survival in chronic myeloid leukemia patients, study says (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - June 5, 2017 Category: Cancer & Oncology Source Type: news

Payments linked to higher odds of doctors prescribing certain cancer drugs
(UNC Lineberger Comprehensive Cancer Center) In preliminary findings (abstract 6510) that will be presented at the American Society of Clinical Oncology Annual Meeting 2017 in Chicago on Saturday, June 3, researchers show that when physicians had to choose between multiple, on-patent drugs for metastatic kidney cancer and chronic myeloid leukemia, they were more likely to prescribe drugs from companies they had received general payments from. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2017 Category: International Medicine & Public Health Source Type: news

TKI Discontinuation Possible for Some CML Patients
Ahead of the 2017 ASCO Annual Meeting, we discuss the discontinuation of TKIs in some chronic myeloid leukemia patients. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2017 Category: Cancer & Oncology Authors: Ehab Atallah, MD Tags: Conferences/ASCO Hematology Chronic Myeloid Leukemia & Lymphoma Source Type: news

Personalized cell therapy combination achieves complete remission in CLL patients
(University of Pennsylvania School of Medicine) Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center (ACC). The team will present the results from its pilot study of this combination therapy during the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract # 193355). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2017 Category: Cancer & Oncology Source Type: news

Cytogenetic Abnormalities Do Not Affect Prognosis in Pediatric CML
Chromosomal abnormalities such as a variant t(9;22) translocation do not appear to have significant prognostic impact on children with chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 22, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies News Source Type: news

Kenya: Kenyan Study Shines New Light On Chronic Myeloid Leukaemia
[The Conversation Africa] Chronic myeloid leukaemia is a type of bone marrow cancer that goes on to affect the blood, then other organs and tissues. Previous research has linked it to exposure to high doses of radiation. The Conversation Africa's Health Editor Joy Wanja Muraya asked a team of Kenyan experts to explain their research into what other factors might predispose people to this type of cancer. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 22, 2017 Category: African Health Source Type: news

Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions
This review will highlight the survival impact that rituximab therapy has had on major lymphoid malignancies, such as diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma. We will also discuss alternative anti-CD20 monoclonal antibodies. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2017 Category: Cancer & Oncology Authors: Jonathan W. Friedberg, MD, MMSc Patrick M. Reagan, MD Tags: Hematologic Malignancies Leukemia & Lymphoma Oncology Journal Review Article Source Type: news

Insurance Status Influences Chronic Myeloid Leukemia Survival Outcomes
Insurance status at the time of chronic myeloid leukemia diagnosis appears to have an influence on survival outcomes, with the uninsured and those on Medicaid having worse overall survival. (Source: CancerNetwork)
Source: CancerNetwork - May 10, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Challenges in Molecular Monitoring for CML Treatment Response
This video examines the challenge in optimizing and standardizing molecular monitoring for patients with chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 2, 2017 Category: Cancer & Oncology Authors: Susan Branford, MD Tags: Chronic Myeloid Leukemia Videos Hematologic Malignancies Source Type: news

New blood cancer study with'outstanding' results
Research reveals'transformative outcomes'for patients with chronic lymphocytic leukemia. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 27, 2017 Category: Science Source Type: news

'Outstanding' results announced from new blood cancer study
(University of Leicester) Research led by University of Leicester and University Hospitals of Leicester NHS Trust reveals 'transformative outcomes' for patients with chronic lymphocytic leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 27, 2017 Category: Cancer & Oncology Source Type: news